• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Blueprint Medicines

edit

Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation™ Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data “revolution”: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.

Milestones

edit

• 
  Blueprint Medicines added Chris Varma as President & CEO.
  Posted 4/11/11 at 6:24pm
• 
  Blueprint Medicines received $40M in Series A funding. (4/11/11)
  Posted 4/11/11 at 6:24pm via blueprintmedicines.com
• 
  Blueprint Medicines — Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate (5/24/12)
  Posted 5/24/12 at 10:05pm via blueprintmedicines.com

Videos

Screenshots

edit

Sources

1. Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments (blueprintmedicines.com) [edit]
Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate (blueprintmedicines.com) [edit]